Skip to search formSkip to main contentSkip to account menu

GR 203040

Known as: GR-203040, GR203040 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Progress in the development of neurokinin 3 modulators for the treatment of schizophrenia: molecule development and clinical progress.
The neuropeptide NK3 receptor is expressed almost exclusively within the mammalian nervous system and its localization is… 
2004
2004
Attenuation of the gerbil writhing response by mu-, kappa- and delta-opioids, and NK-1, -2 and -3 receptor antagonists.
Mu-, kappa- and delta-opioid receptor agonists are reported to attenuate the acetic-acid-induced abdominal constriction response… 
Highly Cited
2000
Highly Cited
2000
Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171 — PET studies in rhesus monkey
1998
1998
Effects of GR203040, an NK1 antagonist, on radiation- and cisplatin-induced tissue damage in the ferret.
1997
1997
The NK1 antagonist GR203040 inhibits cyclophosphamide-induced damage in the rat and ferret bladder.
1997
1997
Effect of single point mutations of the human tachykinin NK1 receptor on antagonist affinity.
Highly Cited
1996
Highly Cited
1996
GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity
Highly Cited
1995
Highly Cited
1995
The broad‐spectrum anti‐emetic activity of the novel non‐peptide tachykinin NK1 receptor antagonist GR203040
1 Following our earlier observations that the tachykinin NK1 receptor antagonist CP‐99,994 is an effective anti‐emetic in ferrets… 
Highly Cited
1995
Highly Cited
1995
The pharmacology of GR203040, a novel, potent and selective non‐peptide tachykinin NK1 receptor antagonist
1 The in vitro and in vivo pharmacology of GR203040 ((2S, 3S)‐2‐methoxy‐5‐tetrazol‐1‐yl‐benzyl‐(2‐phenyl‐piperidin‐3‐yl)‐amine… 
1995
1995
Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity.
The antiemetic, pharmacokinetic, and metabolic profile of CP-99,994, a potent NK1 receptor antagonist, has been carefully… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)